

Supplemental Table 1: Equations for calculation of non-invasive fibrosis models

MODELS	FORMULA
APRI	$= \frac{AST/ULN^*}{Platelet\ count\ (10^9/L)} \times 100$
AST to ALT Ratio	$= AST/ALT$
FIB-4	$= \frac{Age(yr) \times AST(U/L)}{Platelet\ count(10^9/L) \times \sqrt{ALT(U/L)}}$
NAFLD Fibrosis Score	$= -1.675 + 0.037 \times Age(yr) + 0.094 \times BMI(kg/m^2) + 1.13$ $\times [IFG/diabetes = yes] + 0.99 \times AST/ALT\ ratio - 0.013$ $\times platelet(10^9/L) - 0.66 \times albumin(g/dL)$

* We used 31 U/L for male and 19 U/L for female.

Supplemental Table 2: Change in non-invasive models as a function of fibrosis

	Change in fibrosis stage†			p-value‡	
	Regression (n = 74)	No change (n = 126)	Progression (n = 92)	Regression vs. no change	Progression vs. no change
Change in diagnostic model scores (mean)					
APRI score	-0.3 (±0.8)	-0.2 (±0.7)	0.2 (±1.3)	0.34	0.006
FIB-4 score	0.0 (±0.5)	0.1 (±0.7)	0.5 (±1.3)	0.61	<0.001
AST/ALT ratio	0.1 (±0.2)	0.0 (±0.2)	0.1 (±0.3)	0.002	0.001
NAFLD Fibrosis Score	0.5 (±0.7)	0.4 (±1.0)	0.7 (±1.0)	0.83	0.02

† Regression = any decline in fibrosis stage; no change = no change in fibrosis stage; progression = any increase in fibrosis stage.

‡ P-values obtained from ANOVA comparing: the regression group with the no change group among patients with fibrosis stage 1-4 (n = 164); and the progression group with the no change group among patients with fibrosis stage 0-3 (n = 210).

Supplemental Table 3: Change of fibrosis stage from the first to the second biopsies

		Second fibrosis stage					Total
		0	1	2	3	4	
Initial fibrosis stage	0	36	16	8	2	0	62
	1	26	32	19	7	1	85
	2	6	19	19	22	3	69
	3	0	10	11	31	14	66
	4	0	0	0	2	8	10
Total		68	77	57	64	26	292

Supplemental Table 4: Diagnostic performance of FIB4 and NFS at previously published¹ cutoffs for advanced fibrosis[†] (*n* = 1,904)

Fibrosis Model	C-statistic (95% CI)	Model score cutoff‡	At lower cutoff				At upper cutoff				
			Sens. (%)	Spec. (%)	PPV (%)	NPV (%)	Model score cutoff§	Sens. (%)	Spec. (%)	PPV (%)	NPV (%)
FIB-4	0.80 (0.78, 0.82)	1.30	77	67	48	88	2.67	28	97	78	77
NFS	0.78 (0.76, 0.80)	-1.457	83	55	42	89	0.679	30	95	71	78

CI, confidence interval; NPV, negative predictive value; PPV, positive predictive value; sens., sensitivity; spec. specificity.


† Prevalence of advanced fibrosis was 28%.

‡ Fixed at a cutoff closest to and smaller than the recommended cutoff.

§ Fixed at a cutoff closest to and larger than the recommended cutoff.

1. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease . *Clin Gastroenterol Hepatol* 2009;7:1104–1112.


Supplemental Figure 1: Consortium figure of patients in the NASH-CRN




Supplemental Figure 2: Positive and negative predictive values (PPV and NPV) of the diagnostic model at the fixed specificity of 90% at varying proportion of patients with fibrosis ($n = 1,904$)

Prediction of any fibrosis

Positive predictive value (PPV)




Negative predictive value (NPV)




— APRI - - FIB-4 ···· NAFLD Fibrosis Score ····· AST/ALT ratio

Prediction of moderate fibrosis

Positive predictive value (PPV)




Negative predictive value (NPV)




— APRI - - FIB-4 ···· NAFLD Fibrosis Score ····· AST/ALT ratio

Prediction of advanced fibrosis

Positive predictive value (PPV)



Negative predictive value (NPV)



— APRI - - FIB-4 - - - NAFLD Fibrosis Score ····· AST/ALT ratio

PPV and NPV were calculated using the following formulas:

$$PPV = \frac{TP}{TP + FP} = \frac{D^+ \cdot Sens}{D^+ \cdot Sens + D^-(1 - Spec)} = \frac{Prev \cdot Sens}{Prev \cdot Sens + (1 - Prev)(1 - Spec)}$$

$$NPV = \frac{TN}{TN + FN} = \frac{D^- \cdot Spec}{D^- \cdot Spec + D^+(1 - Sens)} = \frac{(1 - Prev)Spec}{(1 - Prev)Spec + Prev \cdot (1 - Sens)}$$




where

D^+ = disease positive; D^- = disease negative;

FN = false negative; FP = false positive; TN = true negative; TP = true positive;

$Prev$ = prevalence; $Sens$ = sensitivity; $Spec$ = specificity

Supplemental Figure 3: Positive and negative predictive values (PPV and NPV) of the diagnostic model at the fixed specificity of 90% at varying proportion of patients with fibrosis ($n = 1,904$)



Members of the Nonalcoholic Steatohepatitis Clinical Research Network

Cleveland Clinic Foundation, Cleveland, OH: Daniela Allende, MD; Srinivasan Dasarathy, MD; Arthur J. McCullough, MD; Revathi Penumatsa, MPH; Jaividhya Dasarathy, MD

Columbia University, New York, NY: Joel E. Lavine, MD, PhD

Duke University Medical Center, Durham, NC: Manal F. Abdelmalek, MD, MPH; Mustafa Bashir, MD; Stephanie Buie; Anna Mae Diehl, MD; Cynthia Guy, MD; Christopher Kigongo, MB, CHB; Mariko Kopping, MS, RD; David Malik; Dawn Piercy, MS, FNP

Indiana University School of Medicine, Indianapolis, IN: Naga Chalasani, MD; Oscar W. Cummings, MD; Samer Gawrieh, MD; Linda Ragozzino, RN; Kumar Sandrasegaran, MD; Raj Vuppalanchi, MD

Saint Louis University, St Louis, MO: Elizabeth M. Brunt, MD (2002-2008); Theresa Cattoor, RN; Danielle Carpenter, MD; Janet Freebersyser, RN; Debra King, RN (2004-2015); Jinping Lai, MD (2015-2016); Brent A. Neuschwander-Tetri, MD; Joan Siegner, RN (2004-2015); Susan Stewart, RN (2004-2015); Susan Torretta; Kristina Wriston, RN (2015)

Swedish Medical Center, Seattle, WA: Maria Cardona Gonzalez; Jodie Davila; Manan Jhaveri, MD; Kris V. Kowdley, MD; Nizar Mukhtar, MD; Erik Ness, MD; Michelle Poitevin; Brook Quist; Sherilynn Soo

University of California San Diego, San Diego, CA: Brandon Ang; Cynthia Behling, MD, PhD; Archana Bhatt; Rohit Loomba, MD, MHSc; Michael S. Middleton, MD, PhD; Claude Sirlin, MD

University of California San Francisco, San Francisco, CA: Maheen F. Akhter, BS; Nathan M. Bass, MD, PhD (2002-2011); Danielle Brandman, MD, MAS; Ryan Gill, MD, PhD; Bilal Hameed, MD; Jacqueline Maher, MD; Norah Terrault, MD, MPH; Ashley Ungermann, MS

University of Washington Medical Center, Seattle, WA: Matthew Yeh, MD, PhD

Virginia Commonwealth University, Richmond, VA: Sherry Boyett, RN, BSN; Melissa J. Contos, MD; Sherri Kirwin; Velimir AC Luketic, MD; Puneet Puri, MD (2009-2017); Arun J. Sanyal, MD; Jolene Schlosser, RN, BSN; Mohammad S. Siddiqui, MD; Leslie Yost-Schomer, RN

Washington University, St. Louis, MO: Elizabeth M. Brunt, MD (2008-2015); Kathryn Fowler, MD (2012-2015)

Resource Centers

National Cancer Institute, Bethesda, MD: David E. Kleiner, MD, PhD

National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD: Edward C. Doo, MD; Sherry Hall, MS; Jay H. Hoofnagle, MD; Jessica J. Lee, MD, MMSc; Patricia R. Robuck, PhD, MPH (2002-2011); Averell H. Sherker, MD; Rebecca Torrance, RN, MS

Data Coordinating Center, Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD: Patricia Belt, BS; Jeanne M. Clark, MD, MPH; John Dodge; Michele Donithan, MHS; Erin Hallinan, MHS; Milana Isaacson, BS; Mariana Lazo, MD, PhD, ScM; Jill Meinert; Laura Miriel, BS; Jacqueline Smith, AA; Michael Smith, BS; Alice Sternberg, ScM; James Tonascia, PhD; Mark L. Van Natta, MHS; Annette Wagoner; Laura A. Wilson, ScM; Goro Yamada, PhD, MHS, MHS, MMS; Katherine Yates, ScM